BCMA-Targeted CAR-T Therapies in Development and Future Perspective
January 30th 2024Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.
Read More
CIBMTR Registry and CARTITUDE-2: Trial of Cilta-Cel in Patients with MM
January 23rd 2024Dr. Abonour and Dr. Raje provide an overview of the results that were presented at ASH 2023 of the CIBMTR registry and CARTITUDE-2 trial which was the study of ciltacabtagene autoleucel (cilta-cel) in patients with MM and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (cohort B).
Read More
Evolving Treatment Landscape of Relapsed/Refractory Multiple Myeloma
January 16th 2024Rafat Abonour, MD briefly summarizes the current treatment landscape for Relapsed/Refractory Multiple Myeloma (R/R MM) and discusses the diverse strategies and advancements in managing this complex disease.
Read More
Highlights from ASH 2023 in Transplant-Eligible NDMM
January 15th 2024Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
Read More